AlloVir Announces Pricing of Upsized Initial Public Offering

Rhea-AI Summary

AlloVir, Inc. (Nasdaq: ALVR) has priced its upsized initial public offering at $17.00 per share, offering 16,250,000 shares of common stock. The total gross proceeds from the offering are projected to be $276.25 million before expenses. Trading began on July 30, 2020, with closing expected on August 3, 2020. A 30-day underwriters’ option exists for an additional 2,437,500 shares. The offering is managed by Morgan Stanley, J.P. Morgan, SVB Leerink, and Piper Sandler.

Positive

• Gross proceeds of $276.25 million will support ongoing clinical trials.
• The offering allows AlloVir to strengthen its position in the cell therapy market.

Negative

• Dilution risk for existing shareholders due to new share issuance.

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of 16,250,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. AlloVir’s common stock is expected to begin trading on The Nasdaq Global Market on July 30, 2020 under the ticker symbol “ALVR.” All of the common stock is being offered by AlloVir. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AlloVir, are expected to be $276.25 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on August 3, 2020, subject to satisfaction of customary closing conditions. AlloVir has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of AlloVir’s common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler & Co. are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204 or email at prospectus-eq_fi@jpmchase.com; from SVB Leerink LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6218, or by email at syndicate@svbleerink.com; or from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Media contact:
Courtney Heath
ScientPR
AlloVirPR@scientpr.com
617-872-2462                                                                                      

Investor contact:
Medha Chadha
AlloVir
ir@allovir.com

FAQ

What is the share price of AlloVir's IPO?

The share price of AlloVir's IPO is set at $17.00 per share.

How many shares is AlloVir offering in its IPO?

AlloVir is offering 16,250,000 shares in its IPO.

What are the gross proceeds from AlloVir's IPO?

The gross proceeds from AlloVir's IPO are expected to be $276.25 million.

When will AlloVir's IPO close?

AlloVir's IPO is expected to close on August 3, 2020.

Who are the underwriters managing AlloVir's IPO?

The underwriters for AlloVir's IPO are Morgan Stanley, J.P. Morgan, SVB Leerink, and Piper Sandler.